Orion shows faith in asthma-COPD drug by delaying filing to unsatisfied EMA
This article was originally published in Scrip
Executive Summary
Orion is to continue development of a budesonide-formoterol formulation, for use with the Easyhaler device in the management of asthma and COPD, even though study results generated so far have failed demonstrate equivalence with a reference product - as required under European Medicines Agency guidelines.